# Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

> **NCT07106892** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)

## Interventions

- **DRUG:** HLX43 Dose 1;
- **DRUG:** HLX43 Dose 2;
- **DRUG:** HLX43 Dose 3;

## Key facts

- **NCT ID:** NCT07106892
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07106892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07106892, "Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07106892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*